EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Burden of chemotherapy‐induced myelosuppression among patients with extensive‐stage small cell lung cancer: A retrospective study from community oncology practices

Lowell Hart, Augustina Ogbonnaya, Kristen Boykin, Kathryn Deyoung, Ray Bailey, Trevor Heritage, Lorena Lopez-Gonzalez, Huan Huang, Lucio Gordan

Cancer Medicine · 2023-04 · 12 (8) · 10020-10030

DOI: 10.1002/cam4.5738 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Medicine, online erschienen am 31.03.2023. Verfasst von Lowell Hart und 8 weiteren Autor:innen. Beteiligte Einrichtung: Florida Cancer Specialists & Research Institute, Florida, Fort Myers, USA. Hauptthemen laut MEDLINE: Small Cell Lung Carcinoma, Bone Marrow Diseases, Lung Neoplasms, Antineoplastic Agents. Die Arbeit wurde bisher 27-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Myelosuppression is a major dose‐limiting complication of chemotherapy for patients with extensive‐stage small cell lung cancer (ES‐SCLC). The objective was to describe the burden of myelosuppression, treatment patterns, and supportive care use among patients with ES‐SCLC treated with chemotherapy in a US community oncology setting.

Methods

This retrospective cohort study used structured electronic medical record (EMR) data from the Florida Cancer Specialists & Research Institute between January 2013 and December 2020. Adult patients with ES‐SCLC who were treated with chemotherapy between September 2013 and November 2020 were identified. The index date was the date of the first chemotherapy‐containing line of therapy (LOT). Patients were followed for a minimum of 30 days after index (unless patient died) until December 31, 2020, or end of activity in the EMR data, whichever occurred first. Incidence and frequency of myelosuppressive episodes/events, treatment patterns, eligibility for red blood cell (RBC) or platelet transfusions, and supportive care use (granulocyte colony‐stimulating factor [G‐CSF], erythropoiesis‐stimulating agents [ESAs], intravenous [IV] hydration) during the follow‐up period were reported.

Results

The study population included 1239 patients. Most (94.0%) patients started first‐line chemotherapy at index. During follow‐up and across all chemotherapy‐containing LOTs, 1222 (98.6%) patients had at least 1 myelosuppressive episode; 62.1% of patients had grade ≥ 3 myelosuppressive episodes in at least one lineage, 33.9% had grade ≥ 3 myelosuppressive episodes in at least two lineages, and 15.5% had grade ≥ 3 myelosuppressive episodes in all three lineages. Supportive care use included 89.7% of patients who received G‐CSF, 24.4% who received ESAs, and 52.1% who received IV volume expansion. Almost one‐third (32.6%) of patients were eligible to receive RBC transfusions based on lab values (hemoglobin < 8 g/dL).

Conclusion

There is a high burden related to multilineage myelosuppression among chemotherapy‐treated patients with ES‐SCLC in the community oncology setting. Reducing myelosuppression could make chemotherapy treatment safer, reduce the need for supportive care, and potentially prevent the treatment of complications.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Small Cell Lung CarcinomaBone Marrow DiseasesLung NeoplasmsAntineoplastic AgentsAdultHumansRetrospective StudiesGranulocyte Colony-Stimulating FactorAntineoplastic Combined Chemotherapy Protocols

Stichwörter der Autor:innen

chemotherapycommunity oncologyextensive-stage small cell lung cancermyelosuppressionretrospectivesupportive care

Substanzen

Granulocyte Colony-Stimulating FactorAntineoplastic Agents

Autor:innen und Institutionen

  • Florida Cancer Specialists & Research Institute, Florida, Fort Myers, USA.
  • Wake Forest University School of Medicine, North Carolina, Winston-Salem, USA.
  • Xcenda LLC, Texas, Carrolton, USA.
  • G1 Therapeutics, Inc., North Carolina, Research Triangle Park, USA.

Zitieren

APA

Hart, L., Ogbonnaya, A., Boykin, K., Deyoung, K., Bailey, R., Heritage, T., Lopez-Gonzalez, L., Huang, H., & Gordan, L. (2023). Burden of chemotherapy‐induced myelosuppression among patients with extensive‐stage small cell lung cancer: A retrospective study from community oncology practices. Cancer Medicine, 12(8), 10020-10030. https://doi.org/10.1002/cam4.5738

Vancouver

Hart L, Ogbonnaya A, Boykin K, Deyoung K, Bailey R, Heritage T, et al. Burden of chemotherapy‐induced myelosuppression among patients with extensive‐stage small cell lung cancer: A retrospective study from community oncology practices. Cancer Medicine. 2023;12(8):10020-10030. doi:10.1002/cam4.5738

BibTeX
@article{Hart2023,
  author = {Hart, Lowell and Ogbonnaya, Augustina and Boykin, Kristen and Deyoung, Kathryn and Bailey, Ray and Heritage, Trevor and Lopez-Gonzalez, Lorena and Huang, Huan and Gordan, Lucio},
  title = {Burden of chemotherapy‐induced myelosuppression among patients with extensive‐stage small cell lung cancer: A retrospective study from community oncology practices},
  journal = {Cancer Medicine},
  year = {2023},
  volume = {12},
  number = {8},
  pages = {10020--10030},
  doi = {10.1002/cam4.5738}
}
Kostenlos starten →